Hum Cell. 2021 May 15.
Ryuto Tsuchiya,
Yuki Yoshimatsu,
Rei Noguchi,
Yooksil Sin,
Takuya Ono,
Akane Sei,
Fumitaka Takeshita,
Jun Sugaya,
Shintaro Iwata,
Akihiko Yoshida,
Seiji Ohtori,
Akira Kawai,
Tadashi Kondo.
Myxofibrosarcoma (MFS) is one of the most aggressive sarcomas with highly complex karyotypes and genomic profiles. Although a complete resection is required in the treatment of MFS, it is often not achieved due to its strong invasive nature. Additionally, MFS is refractory to conventional chemotherapy, leading to poor prognosis. Therefore, it is necessary to develop novel treatment modalities for MFS. Patient-derived cell lines are important tools in basic research and preclinical studies. However, only 10 MFS cell lines have been reported to date. Furthermore, among these cell lines, merely two MFS cell lines are publicly available. Hence, we established a novel MFS cell line named NCC-MFS3-C1, using a surgically resected tumor specimen from a patient with MFS. NCC-MFS3-C1 cells had copy number alterations corresponding to the original tumor. NCC-MFS3-C1 cells demonstrate constant proliferation, spheroid formation, and aggressive invasion. In drug screening tests, the proteasome inhibitor bortezomib and the histone deacetylase inhibitor romidepsin demonstrated significant antiproliferative effects on NCC-MFS3-C1 cells. Thus, the NCC-MFS3-C1 cell line is a useful tool in both basic and preclinical studies for MFS.
Keywords: Drug screening; Myxofibrosarcoma; Patient-derived cancer model; Patient-derived cell line; Sarcoma